![Mark Eisner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Eisner
Director/Board Member at
ZURA BIO LIMITED
Net worth: 142 813 $ as of 29/09/2026
Profile
Dr. Mark Eisner, MD, is a Chief Medical Officer at FibroGen, Inc. Dr. Eisner was previously employed as a Senior Vice President by Genentech, Inc. and a Professor by The University of California, San Francisco. He received his undergraduate degree from Stanford University, a doctorate degree from UC Berkeley School of Public Health and a doctorate degree from the University of Pennsylvania Medical Center.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 30/03/2026 | 12,774 ( 0.01% ) | 142 813 $ | 29/09/2026 | |
| 24/06/2026 | 0 ( -.--% ) | - $ | 29/09/2026 | |
| 16/06/2026 | 0 ( -.--% ) | - $ | 29/09/2026 |
Mark Eisner active positions
| Companies | Position | Start |
|---|---|---|
| ZURA BIO LIMITED | Director/Board Member | 20/02/2026 |
| JADE BIOSCIENCES, INC. | Director/Board Member | 24/06/2026 |
The Genentech Foundation
 The Genentech Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Director/Board Member | - |
Former positions of Mark Eisner
| Companies | Position | End |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Chief Tech/Sci/R&D Officer | 23/04/2026 |
Sonoma Biotherapeutics, Inc.
 Sonoma Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in research, development and manufacturing cell and genetic therapy for autoimmune and degenerative diseases | Chief Tech/Sci/R&D Officer | 31/05/2024 |
| KYNTRA BIO, INC. | Chief Tech/Sci/R&D Officer | 07/09/2023 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Education of Mark Eisner
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
59
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
FibroGen, Inc.
 FibroGen, Inc. Pharmaceuticals: MajorHealth Technology Develops biotechnology-based drugs | Health Technology |
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Genentech Foundation
The Genentech Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
UC Berkeley School of Public Health
 UC Berkeley School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania Medical Center
 University of Pennsylvania Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vir Biotechnology, Inc.
 Vir Biotechnology, Inc. BiotechnologyHealth Technology Develops cures and treatments drug for viral & bacterial diseases | Health Technology |
Aerovate Therapeutics, Inc.
 Aerovate Therapeutics, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Sonoma Biotherapeutics, Inc.
Sonoma Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in research, development and manufacturing cell and genetic therapy for autoimmune and degenerative diseases | Health Technology |
Zura Bio Ltd.
 Zura Bio Ltd. BiotechnologyHealth Technology Operates as a multi-asset clinical-stage biotechnology company that focuses on develops novel medicines for immune and inflammatory disorders | Health Technology |
- Stock Market
- Insiders
- Mark Eisner
